D.E. Shaw & Co
ABCL icon

D.E. Shaw & Co’s AbCellera Biologics ABCL Stock Holding History

D.E. Shaw & Co’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Buy
+45,431
New +$222K ﹤0.01% 4340
2026
Q1 		– Sell
-77,776
Closed -$266K – 4472
2025
Q4 		$266K Buy
77,776
+1,293
+2% +$5.77K ﹤0.01% 4205
2025
Q3 		$385K Buy
76,483
+25,409
+50% +$112K ﹤0.01% 3994
2025
Q2 		$175K Buy
+51,074
New +$127K ﹤0.01% 4070
2024
Q4 		– Sell
-420,240
Closed -$1.09M – 4350
2024
Q3 		$1.09M Sell
420,240
-46,325
-10% -$128K ﹤0.01% 3214
2024
Q2 		$1.38M Buy
466,565
+13,330
+3% +$50.4K ﹤0.01% 2962
2024
Q1 		$2.05M Buy
453,235
+422,602
+1,380% +$2.16M ﹤0.01% 2615
2023
Q4 		$175K Sell
30,633
-404,720
-93% -$1.88M ﹤0.01% 3906
2023
Q3 		$2M Sell
435,353
-77,450
-15% -$471K ﹤0.01% 2562
2023
Q2 		$3.31M Sell
512,803
-955,593
-65% -$6.52M ﹤0.01% 2213
2023
Q1 		$11.1M Sell
1,468,396
-979,008
-40% -$8.89M 0.01% 1279
2022
Q4 		$24.8M Sell
2,447,404
-327,955
-12% -$3.79M 0.03% 785
2022
Q3 		$27.4M Buy
2,775,359
+1,672,839
+152% +$18.4M 0.03% 674
2022
Q2 		$11.7M Buy
1,102,520
+1,073,423
+3,689% +$9.09M 0.01% 1254
2022
Q1 		$284K Sell
29,097
-37,014
-56% -$350K ﹤0.01% 4678
2021
Q4 		$945K Buy
66,111
+40,418
+157% +$613K ﹤0.01% 3975
2021
Q3 		$515K Buy
+25,693
New +$454K ﹤0.01% 4072

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

D.E. Shaw & Co's ABCL Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 45,431 shares worth $357K. The stake represents ﹤0.01% of the portfolio and ranks #4340 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in ABCL as recently as Q4 2025.

D.E. Shaw & Co first reported a position in ABCL in Q3 2021 and has held it in 17 quarters since. The position peaked at $27.4M in Q3 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • D.E. Shaw & Co held 45,431 shares of AbCellera Biologics worth $357K as of Q2 2026.
  • AbCellera Biologics was a new D.E. Shaw & Co position in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4340 holding.
  • D.E. Shaw & Co first reported a position in AbCellera Biologics in Q3 2021 and has held it in 17 quarters since.
  • D.E. Shaw & Co's AbCellera Biologics position peaked at $27.4M in Q3 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.